Filing Analysis
NextCure, Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations and Financial Condition).
- Reporting date: August 6, 2026.
- Period covered: Quarter ended June 30, 2026.
NextCure, Inc. (NXTC) has entered into a definitive merger agreement with Avere Therapeutics, Inc., effectively resulting in a reverse takeover where Avere stockholders will own approximately 98.11% of the combined entity. The transaction includes a significant $150 million financing component and requires stockholder approval for several structural changes.
🚩 Red Flags
- Reverse takeover structure: Existing NXTC shareholders are being heavily diluted (to 1.89%).
- Mandatory Reverse Stock Split: The filing indicates a requirement to amend the certificate of incorporation for a potential reverse stock split.
- Significant Dilution: Pre-merger NextCure stockholders face extreme dilution in the combined entity.
- Termination Fees: Avere owes $2,000,000 plus expenses if they terminate; NextCure's fee is significantly lower at $330,000.
📋 Key Facts
- NextCure to merge with Avere Therapeutics via a two-step merger structure involving Neptune Merger Sub Corp.
- Avere stockholders will own ~98.11% of the combined company; NextCure stockholders will own ~1.89%.
- The transaction is expected to close in Q3 2026, subject to customary closing conditions and stockholder approval.
- A $150 million financing transaction (including Company Notes) is required for consummation.
- NextCure's board will be reconstituted with four members designated by Avere; Avere's CEO will lead the combined company.
- The merger includes a requirement to amend NextCure's certificate of incorporation, including potential redomiciliation and a reverse stock split.
NextCure, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Shareholders approved several key items including director elections, auditor ratification, and an amendment to the company's omnibus incentive plan.
🚩 Red Flags
- The increase in authorized shares under the incentive plan (Proposal No. 4) was approved with a significant number of 'Against' votes (744,709), suggesting some shareholder dissent regarding dilution.
📋 Key Facts
- Stockholders approved the Amendment and Restatement of the 2019 Omnibus Incentive Plan (A&R 2019 Plan).
- The A&R 2019 Plan increases the maximum number of shares authorized for issuance by 80,000 shares.
- The evergreen provision was amended to calculate annual increases based on outstanding shares on a fully diluted basis (including prefunded warrants).
- Two Class I directors, Anne Borgman and John G. Houston, were elected to the Board for three-year terms expiring in 2029.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Executive compensation received an advisory vote approval.
NextCure announced Phase 1 dose escalation data for its drug candidate SIM0505 at the ASCO 2026 conference, showing an objective response rate (ORR) of 55% in gynecologic cancer patients. The company also provided a liquidity update, stating cash is sufficient to fund operations into Q1 2027.
🚩 Red Flags
- Three patients required dose discontinuation due to severe adverse events, including Grade 2 Interstitial Lung Disease (ILD) and Grade 4 thrombocytopenia.
📋 Key Facts
- Phase 1 study (NCT06792552) included 59 patients across the US (n=25) and China (n=34).
- Gynecologic cancer patients (n=20) in the 4.8-8.0 mg/kg dose range showed an ORR of 55% (11/20).
- Ovarian cancer patients showed a 52.9% ORR (9/17) and USC patients showed a 66.7% ORR (2/3).
- Safety profile: Grade 3/4 TEAEs were predominantly hematological; three patients discontinued treatment due to Grade 2 ILD, Grade 3 fungal pneumonia, and Grade 4 thrombocytopenia.
- Cash runway is estimated to last into the first quarter of 2027.
NextCure, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly update on the company's operations and financial condition.
📋 Key Facts
- Reported financial results for the quarter ended March 31, 2026.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, a press release dated May 7, 2026.
- The information is furnished and not deemed 'filed' for Section 18 purposes.
NextCure, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 5, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1 to the filing.
NextCure, Inc. reported preliminary cash positions as of December 31, 2025, and provided clinical program updates for its antibody drug conjugate (ADC) therapies. The company maintains a cash runway into the first half of 2027.
🚩 Red Flags
- Clinical trial delay: LNCB74 proof-of-concept data is pushed back to the second half of 2026.
- Cash runway limited to approximately 18 months (H1 2027).
📋 Key Facts
- Cash, cash equivalents, and marketable securities totaled approximately $41.8 million as of December 31, 2025 (unaudited).
- Company expects current financial resources to fund operations into the first half of 2027.
- SIM0505 Phase 1 dose escalation study data is expected in Q2 2026.
- LNCB74 proof-of-concept data has been delayed from H1 2026 to H2 2026 due to enrollment delays.
NextCure, Inc. entered into an 'at the market' (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $14.5 million of common stock. The proceeds are intended for general corporate purposes, including preclinical studies and clinical trials.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common stock.
📋 Key Facts
- Entered into ATM Agreement with H.C. Wainwright & Co., LLC on December 19, 2025.
- Maximum aggregate sales price of $14,500,000 in common stock.
- Agent (H.C. Wainwright) to receive 3.0% compensation on gross proceeds.
- Proceeds earmarked for general corporate purposes, working capital, preclinical studies, and clinical trials.
NextCure, Inc. completed a $21.5 million private placement of common stock and pre-funded warrants at $8.52 per share on November 14, 2025. The company also issued a liquidity update stating that existing cash is expected to fund operations into the first half of 2027.
🚩 Red Flags
- Significant dilution: The issuance of pre-funded warrants (representing ~2.5x the number of common shares sold) creates substantial potential future dilution.
- Liquidity uncertainty: While management provides a runway to H1 2027, they explicitly note that assumptions may be incorrect and capital could be exhausted sooner.
📋 Key Facts
- Raised approximately $21.5 million in gross proceeds via private placement.
- Issued 708,428 shares of common stock at $8.52 per share.
- Issued pre-funded warrants to purchase up to 1,815,049 shares at a price of $8.519 per warrant.
- H.C. Wainwright & Co. served as the sole placement agent.
- The company entered into a Registration Rights Agreement for the newly issued securities.
- Management estimates existing cash/marketable securities will fund operations into H1 2027.
NextCure, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. This is a routine earnings release filing.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 5, 2025
- The company issued a press release containing financial results (Exhibit 99.1)
NextCure, Inc. announced the resignation of its Chief Scientific Officer, Solomon Langermann, Ph.D., effective September 1, 2025. The company stated the departure was not due to any disagreements regarding operations or policies.
🚩 Red Flags
- Departure of a key scientific officer in a biotech/life sciences company can sometimes signal internal R&D shifts, though no disagreement was cited.
📋 Key Facts
- Solomon Langermann, Ph.D. is resigning from his role as Chief Scientific Officer.
- The resignation is effective September 1, 2025.
- The company explicitly states the departure was not due to disagreements with Company operations, policies, or practices.
NextCure, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal mechanism to furnish the quarterly earnings press release.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The company is furnishing results via Exhibit 99.1 (Press Release)
- Signed by Steven P. Cobourn, Chief Financial Officer
NextCure, Inc. (NXTC) has executed a 1-for-12 reverse stock split effective July 14, 2025. This action follows stockholder approval from the June 20 annual meeting to implement a split within a range of 1:5 to 1:15.
🚩 Red Flags
- Reverse stock split: Often used by micro-cap companies to boost share price to meet exchange listing requirements or avoid delisting.
- Significant dilution/structural change that can signal liquidity or valuation struggles.
📋 Key Facts
- Reverse stock split ratio is 1-for-12.
- Effective date: July 14, 2025, at 12:01 a.m. ET.
- The number of authorized shares remains unchanged at 100 million.
- No fractional shares will be issued; instead, stockholders will receive cash in lieu of fractions based on the previous day's closing price.
- Stock options will have their exercise prices adjusted upward to reflect the split.
NextCure, Inc. has announced a 1-for-12 reverse stock split of its common stock, effective July 14, 2025. This move is typically used by micro-cap companies to increase their share price and maintain compliance with exchange listing requirements.
🚩 Red Flags
- Reverse stock splits are often a defensive measure to avoid delisting due to low share prices.
- Potential for increased volatility and negative market sentiment following the split-adjusted trading start.
📋 Key Facts
- Reverse stock split ratio is one-for-twelve (1:12).
- The split is expected to become effective on July 14, 2025.
- Shares will begin trading on a split-adjusted basis at market open on the effective date.
- No fractional shares will be issued; instead, stockholders will receive cash in lieu of fractions based on the closing price from the last trading day prior to effectiveness.
NextCure, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved a proposal to allow the Board to implement a reverse stock split if deemed necessary. The filing also details the election of three Class III directors and the ratification of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Approval of a Reverse Split Proposal: This is a significant red flag often used to boost share price to meet exchange listing requirements or to attract institutional investors, typically indicating the stock has been trading at very low levels.
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- Stockholders approved the 'Reverse Split Proposal' with 18,166,577 votes in favor and 2,028,946 against.
- Three Class III directors (David Kabakoff, Michael Richman, and Stephen W. Webster) were elected to three-year terms expiring in 2028.
- Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Advisory 'say-on-pay' votes regarding executive compensation and frequency were approved.
NextCure, Inc. entered into a significant licensing agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. and simultaneously conducted a $2.0 million private placement of common stock to an affiliate of the licensee.
🚩 Red Flags
- Private placement conducted with an affiliate of the company's new major licensee (potential related-party transaction/conflict).
- Significant dilution: Issuance of over 4 million shares at a low price point ($0.492) to a strategic partner.
- Heavy contingent liabilities in the form of massive potential milestone payments and royalties.
📋 Key Facts
- Entered into a Licensing Agreement with Hainan Simcere Zaiming Pharmaceutical (Zaiming) on June 13, 2025.
- Licensing includes exclusive worldwide rights (excl. China/HK/Macau/Taiwan) to ADC candidate SIM0505 and non-exclusive use of Zaiming's ADC platform for NextCure antibodies.
- Upfront cash payment of $12 million plus a conditional $5 million due by Dec 31, 2025.
- Potential milestone payments up to $166.5M per product and sales-based royalties up to $535M.
- Conducted a private placement of 4,063,633 shares at ~$0.492 per share for $2.0 million to Simcere Zaiming, Inc.
- Company estimates cash runway extends into mid-2026.
NextCure, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025. The filing serves as a formal vehicle to furnish the press release containing these results.
📋 Key Facts
- Report date: May 1, 2025
- Reporting period: Quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) regarding its financial condition and results of operations.
- Signed by Steven P. Cobourn, Chief Financial Officer.
NextCure, Inc. updated its corporate presentation to provide updates regarding the ongoing clinical trial of its LNCB74 program. The company intends to use these materials in upcoming engagements with the investment community.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- The update specifically concerns the clinical trial progress of LNCB74.
- The company will be engaging with the investment community starting April 10, 2025, using updated presentation materials.
NextCure, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal mechanism to furnish the press release containing these results.
📋 Key Facts
- Report date: March 6, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
NextCure, Inc. received a notice from Nasdaq stating its common stock failed to meet the minimum $1.00 average closing price requirement over the prior 30 consecutive business days. The company has a grace period until July 30, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to maintain listing
- Stock price has fallen below the $1.00 minimum threshold
📋 Key Facts
- Received written notice from Nasdaq on January 31, 2025.
- Failure to meet the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1).
- The company has a grace period until July 30, 2025, to regain compliance.
- Compliance requires a closing bid price of at least $1.00 for ten consecutive business days.
- The company is considering a reverse stock split as a potential method to regain compliance.
NextCure, Inc. announced the successful dosing of the first patient in its Phase 1 clinical study for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) intended to treat multiple cancers.
📋 Key Facts
- First patient dosed in Phase 1 study of LNCB74 on January 10, 2025.
- LNCB74 is a B7-H4-targeting antibody-drug conjugate (ADC).
- The clinical program targets the treatment of multiple cancers.
NextCure, Inc. announced that the FDA has accepted its Investigational New Drug (IND) application for a Phase 1 clinical trial of LNCB74, an antibody-drug conjugate targeting B7-H4.
📋 Key Facts
- FDA acceptance of IND application for LNCB74.
- LNCB74 is a B7-H4-targeting antibody-drug conjugate (ADC).
- The clinical trial will be a Phase 1 study to evaluate the therapeutic for treating multiple cancers.
- Filing date: December 10, 2024.
NextCure, Inc. updated its corporate presentation to reflect the filing of an Investigational New Drug (IND) Application for its product candidate LNCB74. The company intends to use these materials in upcoming engagements with the investment community.
📋 Key Facts
- Filed an Investigational New Drug (IND) Application for product candidate LNCB74.
- Updated corporate presentation dated December 5, 2024.
- Engaging with members of the investment community starting December 5, 2024.
NextCure, Inc. filed an 8-K to furnish presentation materials in connection with investor calls scheduled for November 8, 2024. The filing is a standard regulatory disclosure of non-filed information under Item 7.01.
📋 Key Facts
- The company is hosting calls with the investment community starting November 8, 2024.
- Presentation materials are being furnished as Exhibit 99.1.
- Information provided under Item 7.01 is not considered 'filed' for purposes of liability under the Exchange Act.
NextCure, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- The report date is November 7, 2024.
- The filing pertains to financial results for the quarter ended September 30, 2024.
- The company is an emerging growth company.
- The primary content is a press release attached as Exhibit 99.1.
NextCure, Inc. has filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- The company issued a press release on August 1, 2024, regarding financial results for the quarter ended June 30, 2024.
- The filing is made pursuant to Item 2.02 of Form 8-K (Results of Operations and Financial Condition).
- The report was signed by Steven P. Cobourn, Chief Financial Officer.
NextCure, Inc. held its 2024 Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the election of two Class II directors and the ratification of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Shareholders explicitly voted against the amendment to exculpate company officers, indicating potential dissatisfaction with corporate governance or liability protections.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Elected Elaine V. Jones, Ph.D. and Ellen G. Feigal, M.D. to the Board (Class II) for three-year terms expiring in 2027.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024 with 21,818,499 votes 'For'.
- Stockholders rejected a proposal to amend the Certificate of Incorporation to provide for officer exculpation (Proposal No. 3 received 0 votes 'For').
NextCure, Inc. announced the retirement of its Chief Medical Officer, Dr. Han Myint, effective July 1, 2024. To ensure continuity in clinical trial oversight, the company has entered into a consulting agreement with Dr. Myint to serve on the Scientific Advisory Board through at least July 2025.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a biotech company can create temporary knowledge gaps in clinical development.
📋 Key Facts
- Dr. Han Myint will retire as Chief Medical Officer effective July 1, 2024.
- The Company will provide retirement benefits including salary and healthcare through March 31, 2025.
- A Scientific Advisory and Consulting Agreement was signed on June 18, 2024, effective July 2, 2024.
- Dr. Myint will consult on ongoing clinical trials and serve on the Scientific Advisory Board.
- The consulting term runs through July 2, 2025, with automatic one-year renewals.
NextCure, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: May 2, 2024.
- Period covered: Quarter ended March 31, 2024.
- The company is an emerging growth company.
NextCure, Inc. filed an 8-K to announce its full-year financial results for the fiscal year ended December 31, 2023 and provided presentation materials for investor meetings.
📋 Key Facts
- Company issued a press release regarding FY2023 financial results on March 21, 2024.
- The company is hosting calls with the investment community starting March 21, 2024.
- Presentation materials were provided under Regulation FD disclosure.